The article points out that different cancers respond differently. High-mutation cancers are the most likely to be effectively treated with drug combinations or by using dosing cycles to manage the cancer.

There’s usually a metabolic cost to maintaining any kind of drug resistance. When the drug isn’t present that cost confers no benefit.

As always, cancer isn’t one disease and there won’t be any single silver bullet. Just lots of different strategies, eventually selected by sequencing a specific tumor to determine the most effective one.